• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

    3/6/24 4:35:00 PM ET
    $CSBR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CSBR alert in real time by email

    HACKENSACK, NJ / ACCESSWIRE / March 6, 2024 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the third quarter ended January 31, 2024, on Tuesday, March 12, 2024, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 860900. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 50100, or by accessing the investors section of the company's website within 72 hours.

    About Champions Oncology, Inc.
    Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

    Media Contact:
    Rachel Bunting, MS, MBA
    VP, Global Marketing
    [email protected]

    Website: www.championsoncology.com
    Facebook: www.facebook.com/championsoncology/
    LinkedIn: www.linkedin.com/company/champions-oncology-inc-/
    Twitter: www.twitter.com/ChampionsOncol1
    Instagram: www.instagram.com/championsoncology/

    SOURCE: Champions Oncology, Inc.



    View the original press release on accesswire.com

    Get the next $CSBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CSBR

    DatePrice TargetRatingAnalyst
    9/12/2024$6.00Hold → Buy
    Craig Hallum
    More analyst ratings